Telix Pharmaceuticals Limited, an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), announced the establishment Telix Pharmaceuticals (Japan) Ltd.
Telix Japan is wholly-owned operating subsidiary of Telix Pharmaceuticals Limited. The purpose of the subsidiary is to support the Company’s Japanese clinical and radiopharmaceutical manufacturing activities and to establish a commercial footprint in the Japan, an important market for Telix’s products.
Telix Co-Founder and CEO Dr. Christian Behrenbruch stated, “Japan is one of the most important prospective markets for Telix’s products and our activities in Japan covers a range of manufacturing and collaboration activities with leading Japanese clinical sites and biopharmaceutical companies. The Japanese radiopharmaceutical landscape is evolving rapidly, and we are pleased to have been able to hire two extremely high-caliber executives to lead our development and commercial activity.”
About one month ago, Telix Pharmaceuticals set up a manufacturing partnership with Japanese JFE Engineering Corporation, an engineering and manufacturing company with extensive expertise in the installation of cyclotron infrastructure and radiopharmaceutical manufacturing in Japan. An exclusive agreement suppose to focus on technology transfer and feasibility assessment for producing TLX-250 (girentuximab), an antibody-based diagnostic agent. The parties intended to work together to conduct initial pilot studies at several key Japanese nuclear medicine centres, as well as engage with the Pharmaceuticals and Medical Devices Agency (PMDA)